Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Orthopediatrics (KIDS) EBITDA (2016 - 2025)

Orthopediatrics has reported EBITDA over the past 10 years, most recently at -$8.2 million for Q4 2025.

  • Quarterly results put EBITDA at -$8.2 million for Q4 2025, up 41.86% from a year ago — trailing twelve months through Dec 2025 was -$39.2 million (down 12.08% YoY), and the annual figure for FY2025 was -$39.2 million, down 12.08%.
  • EBITDA for Q4 2025 was -$8.2 million at Orthopediatrics, up from -$9.4 million in the prior quarter.
  • Over the last five years, EBITDA for KIDS hit a ceiling of -$2.8 million in Q2 2021 and a floor of -$14.1 million in Q4 2024.
  • Median EBITDA over the past 5 years was -$6.7 million (2022), compared with a mean of -$7.2 million.
  • Biggest five-year swings in EBITDA: soared 59.44% in 2021 and later crashed 91.03% in 2022.
  • Orthopediatrics' EBITDA stood at -$5.6 million in 2021, then plummeted by 49.42% to -$8.3 million in 2022, then rose by 2.92% to -$8.1 million in 2023, then crashed by 74.25% to -$14.1 million in 2024, then soared by 41.86% to -$8.2 million in 2025.
  • The last three reported values for EBITDA were -$8.2 million (Q4 2025), -$9.4 million (Q3 2025), and -$10.7 million (Q2 2025) per Business Quant data.